The endogenous cannabinoid system is a new signaling system composed by the central (CB 1) and the peripheral (CB 2) receptors, and several lipid transmitters including anandamide and 2-arachidonylglycerol. This system is the target of natural cannabinoids, the psychoactive constituents of Cannabis sativa preparations (marijuana, hashish). Acute and chronic cannabis exposure has been associated with subjective feelings of pleasure and relaxation, but also to the onset of psychiatric syndromes, a decrease of the efficacy of neuroleptics and alterations in the extrapyramidal system regulation of motor activity. These actions points to a tight association of the cannabinoid system with the brain dopaminergic circuits involved in addiction, the clinical manifestation of positive symptoms of schizophrenia and Parkinson's disease. The present work discuss anatomical, biochemical and pharmacological evidences supporting a role for the endogenous cannabinoid system in the modulation of dopaminergic transmission. Cannabinoid CB 1 receptors are present in dopamine projecting brain areas. In primates and certain rat strains it is also located in dopamine cells of the A8, A9 and A10 mesencephalic cell groups, as well as in hypothalamic dopaminergic neurons controlling prolactin secretion. CB 1 receptors co-localize with dopamine D1/D 2 receptors in dopamine projecting fields. Manipulation of dopaminergic transmission is able of altere the synthesis and release of anandamide as well as the expression of CB 1 receptors. Additionally, CBlreceptors can switch its transduction mechanism to oppose to the ongoing dopamine signaling. Acute blockade of CB 1 receptor potentiates the facilitatory role of dopamine D 2 receptor agonists on movement. CB 1 stimulation results in sensitization to the motor effects of indirect dopaminergic agonists. The dynamics of these changes indicate that the cannabinoid system is an activity-dependent modulator of dopaminergic transmission, an hypothesis relevant for the design of new therapeutic strategies for dopamine-related diseases such as the psychosis and Parkinson's disease.
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I N T R O D U C T I O N
The endocannabinoid system in the brain is configured by the central cannabinoid receptor, CB 1 (Devane et al., 1988) , and the endogenous ligands anandamide (Devane et al., 1992) and 2-arachidonyl glycerol (Mechoulam et al., 1995; Stella et al., 1997) . Acute and chronic effects of Cannabis sativa derivatives on central nervous system 24 FERNANDO RODR [GUEZ DE FONSECA et al. functioning are mediated through the action of THC, its main psychoactive constituent (Gaoni and Mechoulam, 1964) on specific brain CB 1 cannabinoid receptors. The potential adverse effects of Cannabis consumption may include, among others, anxiety-like disorders (Halikas et al., 1985; Rodrfguez de Fonseca et al., 1997) , increased risk for the onset of psychotic syndromes (Andr6asson et al., 1987; NufiezDomfnguez and Gurpegui-Fernfindez, 1997 ) and a decrease of the therapeutic effectiveness of neuroleptics (Knudsen and Vilmar, 1984) . The psychopathological features associated to acute and chronic Cannabis exposure points to a tight connection between the endogenous dopamine transmission systems (dopamine-releasing and dopamine receptor-expressing neurons) and the endogenous cannabinoid system. Dopamine neurons, mainly those from the nigrostriatal and the mesocorticolimbic pathways, have been considered relevant for the process of reward and stress signals, drug addiction, and the positive symptoms of schizophrenia (Grace, 1991; Le Moal and Simon, 1991) .
There is a growing literature confirming the above proposed contribution of the endogenous cannabinoid system in dopamine-related diseases such as addiction (Gardner and Vorel, 1998; , stress ), psychoses (Andr6asson et al., 1987 Knudsen and Vilmar, 1984; Nufiez-Domfnguez and Gurpegui-Fernfindez, 1997) or extrapyramidaI disorders such as Parkinson's disease or dystonias (Clifford, 1983; Glass et al., 1997; Rodrfguez de Fonseca et al., 1994b and . However, in order to understand that contribution to dopamine-related neuropsychiatric conditions we need to solve one of the striking challenges in the cannabinoid field: the explanation of the physiological rote of a system densely present in dopamine-projecting brain areas, with a highly preserved neurobiological properties throughout the evolution, but with a low tonic activity as revealed by functional antagonism studies (Howlett, 1995; Gueudet et al., 1995; Navarro et al., 1997) . In the present work we will briefly discuss the biochemical, anatomical and behavioral components of the interaction between dopamine and endocannabinoid systems. We will propose a model under which explore the potential relevance of these interactions for the understanding and treatment of neurodegenerative disorders such as Parkinson's disease, and psychiatric syndromes such as schizophrenia.
NEURONATOMICAL ANALYSIS OF THE PRESENCE OF CANNABINOID RECEPTORS IN BRAIN DOPAMINE CIRCUITS
Cannabinoid CB 1 receptors are distributed in the mammalian brain at a higher levels than any other known G-protein-coupled receptor (Herkenham et al., 1990; Mailleux and Vanderhaeghen, 1992; Matsuda et al., 1990 and Tsou et al., 1998) . They are expressed in areas of the central nervous system that contribute to the control of movement (caudate-putamen, globus pallidum, entopeduncular nucleus, substantia nigra and cerebellum), memory and cognition (hippocampal formation, cingulate cortex), processing of emotions and motivational responses (amygdalar complex, nucleus accumbens, olfactory cortex), pain perception (central gray matter, dorsal horn of spinal medulla), and neuroendocrine integration (paraventricular, arcuate, supraoptic and ventromedial hypothalamic nuclei). (Mailleux and Vanderhaeghen, 1992; Matsuda et al., 1993) . The analysis of this distribution reveals that the pharmacological profile described for CB 1 agonists (Dewey, 1986; Howlett, 1995) matches with the anatomical distribution of both CB 1 -agonist binding sites and CB 1 mRNA. Interestingly, cannabinoid receptor antagonist SR141716A (Rinaldi-Carmona et al., 1994) has been used to confirm this specific neuroanatomical profile, and has revealed the existence of an endogenous cannabinoid tone in the hippocampus, substantia nigra and limbic sys-FIGURE 1 Neuroanatomical distribution of CB I receptors in the substantia nigra of the Wistar rat brain, as revealed by immunocytochemical double labelling and confocal microscopy. Red flourescence corresponds to tyrosine hydroxylase (TH) immunopossitive cells, whereas green flourescence reveals the location of cannabinoid CB l receptors. Double labelling appears as a yellow/orange flourescence. Details on the method have been previously described . A. Panoramical view of the substantia nigra pars compacta showing cells labelled only for TH (white arrow) or double-labelled for TH and CB 1 (yellow arrow). B and C. Higher magnification of the external border of the pars compacta, showing those cells and cells only labelled for CB 1 receptor (red arrow). D. Panoramical view of the substantia nigra showing TH-labelled dendrites from the pars compacta (white arrow) penetrating into the pars reticulata which expres CBl-receptor immunopossitive terminals (white arrow) (See Color Plate I at the back of this issue) tem which also correlates with the neuroanatomical distribution of CB 1 receptors (Gessa et al., 1997; Gueudet et al., 1995; Navarro et al., 1997; Rodrfguez de Fonseca et al., 1997) .
Although cannabinoid CB 1 receptors were formerly described in specific brain locations related to dopamine circuits, such as the basal ganglia, the extended amygdala and the limbic cortices, they seemed to be absent in brain dopaminergic neurons (Herkenham et al., 1990; Matsuda et al., 1993) . However recent studies (Ong and Mackie, 1999 ; Rodrfguez deFonseca et al, unpublished, see Figure 1 ) have revealed strain and species-specific differences in the distribution of CB 1 receptors in brain dopamine cells. We have found that in the Wistar rat, as opposed to the deeply studied Sprague-Dawley strain (Herkenham et al., 1991; Matsuda et al., 1993; Tsou et al., 1998) , dopaminergic cells express low to moderate amount of CB 1 receptors. Similar findings were reported in the primate brain, (Ong and Mackie, 1999) , supporting the possibility of a direct action of CB 1 receptor agonists on dopamine neurons, as suggested in early electrophysiological studies using pharmacological antagonists of the CB 1 receptor (French et al., 1997; Guedet et al., 1995) It is generally accepted is that CB 1 receptors co-localize with dopamine receptors in neurons of dopamine-projecting fields such as the basal ganglia and limbic cortex (Herkenham et al., 1991; Mailleux and Vanderhaeghen, 1993) . Both kind of receptors are mostly found in GABAergic projecting neurons, (although glutamatergic neurons expressing CB 1 receptors have been reported, including those from the cortex and the subthalamic nuclei, Safiudo-Pefia and Walker, 1997) . In the basal ganglia circuitry, GABAergic medium-spiny striatal neurons that express CB 1 receptors, receive afferents from dopamine neurons of the substantia nigra pars compacta and show co-expression of dopamine D 1, D 2 and D 3 receptors (Surmeier et al., 1996) . Their axon terminals innervating the globus-pallidum, substantia nigra pars reticulata and subthalamic nucleus contain high amounts of CB 1 receptors (Herkenham et al., 1991) . Figure 2 illustrates a typical image of functional cannabinoid CB 1 receptors in the mesencephalom of the rat, mapped by CB 1 agonist-stimulated GTPyS incorporation (Sim et al., 1996) . The dense activation of the substantia nigra, mainly the pars reticulata, indicates the potential relevance of the endogenous cannabinoid system in basal ganglia functioning.
FUNCTIONAL ASPECTS OF CANNABINOID-DOPAMINE

INTERACTIONS
In the brain areas described above, relevant for most neuropsychiatric diseases, CBlstimulation might either directly modulate the activity of dopaminergic neurons or interfere with the transduction of dopamine signal at postsynaptic dopamine receptors co-localized with CB 1. The presence of CB 1 receptors in dopamine cells allow a direct regulation of dopaminergic activity (i.e. spontaneous and evoked firing, synthesis and release of dopamine, etc...) by the endogenous cannabinoid system. Several experimental approaches have shown both possibilities (for review see Gardner and Vorel, 1998; Rodrfguez de Fonseca et al, 1998) . Interaction between dopamine receptors and CB 1 receptors has a neurobiological support in the similar structure of both receptorial systems. These receptors belong to the family of G-protein coupled receptors for neurotransmitters (Matsuda et al., 1990; Howlett, 1995) . Both types of receptors are coupled to the same transduction systems, including the control of cAMP synthesis, and the regulation of Ca2+and K + channels (Hampson et al., 1995; Howlett, 1995; Mackie and Hille, 1992) . FIGURE 2 Coronal autoradiography showing the stimulatory effects of the cannabinoid CB 1 receptor agonist WIN 55,212-2 on GTPT-S incorportion in the mesencephalon of the rat brain. WIN 55,212-2 (5 I~M) produced a marked incorporation of GTPT-S in the substantia nigra of the rat brain, which appear heavy labelled (SN, red color). Other areas specifically labelled were the ventral tegmental area (VTA), the periaqueductal graymatter (PAG) and the superficial layer of the superior colliculus (SC) (See Color Plate II at the back of this issue)
Dopamine-cannabinoid interactions in the nigrostriatal system
At the level of the different d o p a m i n e circuits, the role of the endogenous cannabinoid system seemed to be different. In the nigrostriatal pathw a y most of the effects observed after CB 1 receptor stimulation point to an indirect regulation of dopaminergic activity, through the action of CB1 receptor expressing GABAergic neurons of the outflow nuclei of basal ganglia (Maneuf et al., 1996 , N a v a r r o et al., 1993b; Pertwee and Greentree, 1988) . Striatal d o p a m i n e turnover was not found to be affected after acute T H C exposure neither in Sprague-Dawley (Rodrfguez de Fonseca et al., 1992) nor in Wistar rats (Navarro et al., 1993b) . However, acute systemic administration of cannabinoid receptor agonists were found to induce a small increase in the spontaneous activity of nigrostriatal dopaminergic neurons measured by either extracellular recordings (French et al., 1997) or by in vivo v o l t a m m e t r y in the striaturn (Ng Cheong et al., 1988) . The direct or indirect nature of these effects remains to be conclusively determined. However, a recent 28 FERNANDO RODRIGUEZ DE FONSECA et al. study has partially clarified the links between the endogenous cannabinoid system and dopamine transmission. . In this study we have demonstrated by in vivo microdialysis that the extracellular levels of anandamide in the dorsal striatum are greatly increased after the activation of dopamine D2family of receptors (i.e. after quinpirole infused by reverse dialysis), but not after stimulation of dopamine D 1 receptors (i.e. after infusion with the D 1 agonist SKF 38393). The D 2 -receptor evoked anandamide release may serve to limit the extent of behavioral activation induced by dopamine in the striatum. These findings are in agreement with other reports showing an increased behavioral response to the indirect dopamine receptor agonist amphetamine in animals chronically treated with the cannabinoid receptor agonist THC and displaying down-regulated CB 1 receptors (Gorriti et al., 1999; Rodrfguez de Fonseca et al., 1994a) . As shown in figure 3 , the pretreatment with the CB 1 antagonist SR141716A potentiates the stimulation of motor behavior elicited by systemic administration of quinpirole. This effect was not observed when the facilitatory effect on movement was induced by a D 1 agonist (Figure 4 ). Other laboratories have described pharmacological interactions between dopamine D 2 receptor and cannabinoid CB 1 receptors which support this model. Thus, the group of J.M. Walker has shown that regional administration of D 2 family of agonists opposes the behavioral responses to the injection of CBlagonists (Safiudo-Pefia et al., 1996; Safiudo-Pefia and Walker, 1998) .
Although the triggering of anandamide release seems to be dependent on D 2 receptor stimulation, the dopamine D 1 receptors plays also an important role in these cannabinoid-dopamine interaction. Thus, a previous report (Mailleux and Vanderhaeghen, 1993) demonstrated that the chronic blockade of D 1 receptors, which induce a compensatory hyperactivity in nigrostriatal dopaminergic cells, dramatically upregulated the expression of the CB 1 receptor mRNA in the dorsal striatum. Additional behavioural studies showed that CB 1 agonists blocked rotational behaviour induced by dopamine D 1 receptor agonists (Anderson et al., 1995) whereas repeated stimulation of dopamine D 1 receptors (Rodriguez de Fonseca et al., 1994) resulted in a potentiation of cannabinoid agonist-induced catalepsy and akinesia. These data suggest the existence of differences in the interactions between dopaminergic and cannabinoid systems regarding the different receptors involved. A current working hypothesis on the interaction between cannabinoid and dopamine receptors in the striatum is depicted in figure 5 .
Whether these pharmacological effects are selective for the dorsal striatum or appear in other brain areas remains to be determined. Regional differences on the role of CB 1 receptors in controlling basal ganglia activity at mesencephalic sites have been proposed because of the dense presence of cannabinoid receptors in the substantia nigra (Glass et al., 1997a) . Thus, it has been found that cannabinoids activate substantia nigra pars reticulata neurons, probably by inhibiting GABA release from striatonigral projections through the stimulation of presynaptic CB 1 receptors (Tersigni and Rosemberg, 1996) . This blockade of GABA release may be responsible for the in vivo observed increased activity of nigrostriatal dopamine neurons after acute cannabinoid exposure since they are under the influence of the striatonigral pathway (French et al., 1997; Gueudet et al., 1995; Ng Cheong et al., 1988 ). An additional indirect source of regulatory inputs to the substantia nigra comes from the striatum through the subthalamic nucleus, whose activity may be modulated by CBlstimulation (Safiudo-Pefia and Walker, 1997) . On the other hand, cannabinoid receptors in the striatum seem to be negatively coupled to K+-stimulated (Navarro et al., 1993) or electrically-evoked (Cadogan et al., 1997) Blockade of CB 1 receptors with SR141716A potentiates quinpirole-induced alterations on behavior, supporting for a role of the endogenous cannabinoid system in regulating dopamine facilitation of motor behavior. P < 0.05 vehicle versus SR141716A-treated animals, # P < 0.05 versus vehicle-treated (0 dose) animals of the same pretreatment, Newman-Keuls ties will then establish the nature of the actions of CB 1 agonists on the dopamine release in the striatum. Pharmacological manipulations of the acute sensitivity to cannabinoids by concurrent administration of GABAA and GABAB receptor acting drugs (Pertwee and Greentree, 1988; Romero et al., 1995) support the involvement of GABA neurons in the mediation of cannabinoid effects. This contribution can also be deduced from the finding of CB 1 receptor agonist-induced changes in striatal dopamine receptors (Navarro et al., 1993b; Rodrfguez de Fonseca et al., 1992) or by the profound alterations in neuropeptide gene expression found in striatal GABAergic cells of CB 1 receptor-knockout mice (Steiner et al., 1999) .
FIGURE 4 Lack of effects of pretreatment with the cannabinoid CB 1 receptor antagonist SR141716A (1 mg/kg, i.p. 30 min. prior to second drug administration) on the acute facilitatory effects of the dopamine D 1 receptor agonist SKF 38393 (5 mg/kg, s.c.) on motor activity in male Wistar rats. Data were expressed as total time spent in absolute quietness (immobility, upper pannels). They were collected at different times (5, 30, 60 or 120 min) after the injection of the D1 agonist. P < 0.05 versus saline-treated animals, Newman-Keuls
Dopamine-cannabinoid interaction in the mesocorticolimbic circuits
The mesocorticolimbic dopaminergic system has been found to be more sensitive than the nigrostriatal p a t w a y to the acute administration of cannabinoids (Gardner and Vorel, 1998) . First descriptions of THC actions in the brain pointed to an stimulation of mesocorticolimbic dopaminergic activity (Chen et al., 1990; ) . Direct extracellular recordings showed that systemic administration of CB1 agonists increased the activity of ventral tegmental area dopaminergic neurons (French et al., 1997) , associated to an increased dopamine release in the mesolimbic targets (Chen et al., 1990; Gardner et al., 1988; Gardner and Vorel 1998 (Gueudet et al., 1995) , whereas ~t-opioid receptor antagonists (naloxone, naloxonazine) block the increased dopamine release induced by CB1 agonists administration, acting probably both at the ventral tegmental area neurons (Tanda et al., 1997) and at their projecting terminals in the nucleus accumbens (Chen et al., 1990; Gardner and Vorel, 1998 ). An interesting additional hypothesis is the possible glucocorticoid dependence of CB1 agonists-induced mesolimbic activation. Cannabinoids are chemical stressors which activate the pituitary adrenal axis by stimulating ACTH release (Martfn-Calder6n et al., 1998) . They also induce anxiety-like responses . Acute stress is associated with a rapid activation of mesolimbic circuitry that can be mediated by glucocorticoid receptors present in mesolimbic dopaminergic neurons (Piazza et al., 1996) . Whether cannabinoid-induced activation of mesolimbic activity depends on the activation of pituitary-adrenal axis remains to be conclusively determined, but its demonstration may help support clinical observations on the role of Cannabis comsumption as a vulnerability factor for the onset of psychosis or drug addiction (Andreasson et al., 1987; Rodrfguez de Fonseca et al., 1997) .
CANNABINOID-DOPAMINE INTERACTIONS AND DOPAMINE-RELATED DISEASES: WHAT IS NEXT?
As described above, endogenous cannabinoids are local mediators released to regulate information processing within the main relays of the basal ganglia nuclei. The suggested constitutive activity of the CB1 receptor and its potential bidirectional coupling to the adenylate cyclase suggest that this regulatory function affects processes of opposed nature within the striatum, indicating a potential role for this system as an homeostatic set-point mechanism (Glass and Felder, 1997b; Rodrfguez de Fonseca et al., 1998) . The induction of a functional blockade of neurotransmitter uptake processes derived from CB 1 stimulation can affect to neurotransmitters of opposed nature, such as glutamate and GABA, supporting again this buffering role for the endogenous cannabinoid signalling within striatum (Maneuf et al., 1996) . Much work is needed in order to identify the potential regional variabilities in these mechanisms, as well as the pathological conditions on which a clear contribution of the endogenous cannabinoid system may enhance our knowledge of neurological disorders. The research findings discussed in this manuscript suggest that the endogenous cannabinoid system may serve as a target for the development of new strategies for the treatment of dopamine-related diseases, such as motor syndromes. Among those movement disorders, Parkinson's Disease and neuroleptic-induced dyskinesias and dystonias are firmly clinical entities that may be benefitiated from therapy based on the endogenous cannabinoid system, together with Gilles de la Tourette syndrome and Huntington's chorea . As a potential practical utility of the model we can propose cannabinoid agonist for reducing unwanted effects of L-DOPA or dopaminergic agonists in Parkinson's disease or neuroleptic associated tardive dyskinesias, as well as a cannabinoid antagonist for reducing the effective dose of L-DOPA or dopamine agonists needed to alleviate akinesia Rodrfguez de Fonseca et al., 1998) .
Besides motor disorders several neuropsychiatric conditions could also benefit from the availability of new compounds acting at the cannabinoid receptors, such as new and selective antagonists. That goal can also be addressed by designing drugs which may interfere with new 32 FERNANDO RODRIGUEZ DE FONSECA et al.
FIGURE 5 A proposed model for the interactions between dopaminergic transmission and the endogenous cannabinoid system in the dorsal striatum. Dopamine released from axon terminals of substantia nigra pars compacta neurons facilitates motor behavior through the activation of both dopamine D 2 and D 1 receptors located in medium-spiny GABAergic neurons of the dorsal striatum. Simultaneously, activation of dopamine D 2 receptors triggers the release of anandamide from a plasmalemma precursor, which in turn limited the activatory effects of dopamine by stimulating CB 1 receptors. Although depicted as a postsynaptic mechanism, anandamide could be originated through the activation of presynaptic D 2 receptors, and eventually may act at presynaptic CB 1 receptors m o l e c u l a r m e c h a n i s m s i n v o l v e d in c a n n a b i n o i d h y p e r d o p a m i n e r g i c state. A d e p i c t e d in figure 5, t r a n s m i s s i o n , s u c h as the r e c e n t l y d e s c r i b e d a n a n d a m i d e can act as a local m e d i a t o r r e g u l a ta n a n d a m i d e t r a n s p o r t e r (Beltramo et al., 1997) .
ing d o p a m i n e activity. If a n a n d a m i d e release is This latest t a r g e t has o p e n m u l t i p l e possibilities for the t r e a t m e n t of d o p a m i n e -r e l a t e d diseases. A c a r d i n a l e x a m p l e c o u l d be the acute s y m pt o m s of s c h i z o p h r e n i a , w h i c h are c u r r e n t l y a t t r i b u t e d , a m o n g other m e c h a n i s m s , to an also t r i g g e r e d in cortical areas u p o n d o p a m i n e D 2 r e c e p t o r activation, as d e c r i b e d in the d o r s a l s t r i a t u m , a n e n h a n c e m e n t of a n a n d a m i d e levels t h r o u g h the p h a r m a c o l o g ical b l o c k a d e of a n a n d a m i d e u p t a k e or h y d r o l y -sis may act as a neuroleptic through its inhibitory action on dopamine receptor-evoked responses. In support of this hypothesis, preliminary reports have described the presence of elevated levels of anandamide in the cerebrospinal fluid of schizophrenia patients (Leweke et al., 1999) . An additional advantage of such therapeutic approach derives from the fact that anandamide is a partial agonist: the uptake blocker-induced rise in synaptic anandamide may not produce the unwanted side effects, including catalepsy, acute stress-like reactions or the fort receptor desensitization that characterize the action of full CB1 receptor agonists (Dewey, 1986; Howlett, 1995) .
The buffering effects of cannabinoids on synaptic transmission processes points to a neuroprotectant role for drugs aimed to potentiate cannabinoid transmission. Although glucocorticoid-dependent neuronal loss in the hippocampus has been found in rats after chronic treatment with THC (Landfield et al, 1988) neuroprotective actions derived of cannabinoid CB 1 receptor stimulation have been described both in vivo and in vitro (Nagayama et al., 1999) . These findings indicate that a rational use of drugs aimed to the cannabinoid CBlreceptor may protect neurons from different types of injuries derived of overstimulation of glutamate or dopamine release in central synapses.
